Viesosios istaigos Vilniaus universiteto ligonines Santaros kliniku filialas Nacionalinis vezio centras
- Address
- Santariskiu G. 1, Vilniaus M. Sav., 08406 Vilnius, Lithuania
National Cancer Institute - Vilnius University Hospital Santaros Klinikos
The National Cancer Institute, a branch of Vilnius University Hospital Santaros Klinikos, represents Lithuania's premier cancer research and treatment center. This institution specializes in conducting advanced Phase 3 clinical trials across multiple oncology disciplines, with particular expertise in immunotherapy combinations and novel targeted therapies for solid tumors.
- Lung cancer research, including both small cell and non-small cell lung cancer with innovative immunotherapy approaches
- Gastrointestinal malignancies, particularly microsatellite instability-high colorectal cancer
- Genitourinary oncology, focusing on advanced metastatic castration-resistant prostate cancer
The center demonstrates exceptional capabilities in evaluating combination immunotherapy regimens, including pembrolizumab-based protocols and novel therapeutic agents. Their research portfolio encompasses both adjuvant settings for resected cancers and advanced metastatic disease stages, reflecting comprehensive expertise in managing cancer across the treatment continuum. The institute's participation in international multi-center trials underscores its commitment to advancing precision oncology and improving outcomes for patients with difficult-to-treat malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 51 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC9trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 79 other sites in Lithuania
Therapeutic Area Benchmark — Lithuania
Select a therapeutic area to compare against other sites in Lithuania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Lithuania
Market Share
Country: Lithuania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Viesosios istaigos Vilniaus universiteto ligonines Santaros kliniku filialas Nacionalinis vezio centras
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 12 | Unknown | 2018-08-24 | 2025-07-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.